一分钟看懂
这是一项关于卵巢癌的II 期研究，登记的药物或干预包括Pamiparib；Surufatinib，当前状态为招募中。登记地点显示中国合肥有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pamiparib；Surufatinib · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为女性，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Cancer Hospital · 合肥
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Before any procedure of the test is started, informed consent must be provided and filed in the research center.
- * Female subjects ≥ 18 years of age.
- * Biopsy obtained by open surgery, laparoscopic surgery or thick needle puncture, pathologically confirmed as high-grade serous or endometrioid ovarian cancer, peritoneal cancer, or fallopian tube cancer (hereinafter referred to as ovarian cancer), FIGO stage III-IV.
- * Detect tissue samples or blood samples through a testing agency designated by the research center to determine the HRR-related gene mutation or HRD mutation status of patients.
- * The blood and tissue samples of patients before, during, and after treatment can be obtained, and the subjects agree to submit the blood and tissue samples to the Center for the expanded research purpose of the trial, such as possible gene-related research or tumor marker related research.
- * At least one lesion can be measured by CT/MRI.
- * The professional gynecological oncologists appointed by each center should judge the patients who can not achieve R0 tumor reduction or can not tolerate surgery.
- * The criteria for failure to achieve R0 tumor reduction include but are not limited to:Fagotti endoscopic score ≥ 8 points；When the laparoscopic evaluation method is difficult to implement, the upper abdomen CT score can be ≥ 3 points;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05652283；登记信息更新于 2026-10-02；本站同步于 2026-10-08。